Ποια είναι η τιμή για TME Pharma N.V. (ALTME)

Η τιμή για TME Pharma N.V. (ALTME) είναι $0.09489241

Ποια είναι η κεφαλαιοποίηση αγοράς για TME Pharma N.V. (ALTME)

Η κεφαλαιοποίηση αγοράς για TME Pharma N.V. (ALTME) είναι $8.94M

TME Pharma N.V. (ALTME) Τιμή και Κεφαλαιοποίηση Αγοράς

TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.

Η τιμή για ALTME	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$57,880.05 $8.94M	NVDA	$5.452T	+60,995,345.99%
$47,668.54 $8.94M	AAPL	$4.490T	+50,234,204.30%
$44,190.42 $8.94M	GOOG	$4.162T	+46,568,871.39%
$39,030.09 $8.94M	MSFT	$3.676T	+41,130,785.35%
$30,077.15 $8.94M	AMZN	$2.833T	+31,695,954.80%

Η τιμή για ALTME

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$57,880.05 $8.94M